Abstract:Integrin αIIbβ3 (previously called glycoprotein [GP] IIb/IIIa) is a transmembrane GP receptor, which plays a crucial role in blood coagulation by mediating platelet aggregation.[1] [2] After activation, this receptor initiates platelet aggregation rapidly through changing its conformation and introducing the interaction of platelets with a wide array of ligands such as fibrinogen, fibronectin, and von Willebrand factor (VWF). Germline mutations in genes encoding the subunits of the complex, integrin subunit α 2b ( ITGA2B ) and integrin subunit β 3 ( ITGB3 ), have been reported mainly in the platelet-type bleeding disorder Glanzmann thrombasthenia (GT).[3] GT is a congenital disease that follows an autosomal recessive inheritance pattern and exhibits failure or deficiency of platelet aggregation, although with normal platelet counts and morphology.[4] However, several αIIbβ3 variants have also been identified in patients with congenital macrothrombocytopenia, a genetically heterogeneous group of rare disorders characterized by abnormal giant platelets, reduction of platelets, and bleeding tendency with variable severity.[5] Our case is a 13-year-old boy who was referred to our hospital because of hemostatic difficulty after a first episode of epistaxis. His platelet count was 79 × 10 9 /L (normal range: 150–407 × 10 9 /L); the mean platelet volume (MPV) and platelet distribution width (PDW) were close to the upper limit of the reference intervals (MPV: 13.7fL, normal range: 9.0–13.8 fL, PDW: 21.5 fL, normal range: 9.8–21.9 fL). Six months later, the patient was referred to our hospital again due to sporadic petechia of skin. At that time, routine blood test of the patient showed mild reduction in platelet count (102 × 10 9 /L), with no abnormalities of MPV (12.9 fL) and PDW (18.6 fL). His blood cell smear identified a few giant platelets (4 in a standard automated smear in Mindray blood analyzer MC-80), while without obvious reduction of cytoplasmic granules ([Fig. 1A] and [B]). Except for a slight rise near the upper boundary of activated partial thromboplastin time (37.0 seconds; normal range: 25.1–36.5 seconds), other coagulation indicators, including prothrombin time (PT), prothrombin activity, fibrinogen, thrombin time (TT), and international normalized ratio, were all within normal ranges. VWF level and activity were also within normal limits. Platelet aggregation induced by adenosine diphosphate (ADP), collagen, adrenalin, or arachidonate were each substantially reduced ([Fig. 2A]), to varying degrees (ADP: 9.1%, collagen: 17.7%, adrenalin: 28.6%, arachidonate: 1.0%), whereas aggregation induced by ristomycin (ristocetin) was close to normal level (52.2%, [Fig. 2B]), only slightly lower than the bottom of normal range (55.0–100.0%). In addition, tests for autoimmune antibodies were negative for common anti-platelet antibodies, including GPIX (CD42a), GPIB (CD42b), GPIIB (CD41), GPIIIA (CD61), and GMP140 (CD61p). Detailed laboratory results are summarized in [Table 1]. Assays Proband's results Reference interval Blood cell counts[a] Platelet count, ×10 9 /L 102.0 150.0–407.0 MPV, fL 12.9 9.0–13.8 PDW, fL 18.6 9.8–21.9 Thrombosis/hemostasis tests[b] PT, s 12.3 9.4–12.5 Prothrombin activity, % 97 80–130 INR 1.04 0.85–1.15 Fibrinogen, g/L 2.52 2.38–4.98 aPTT, s 37.0 25.1–36.5 TT, s 15.1 10.3–16.6 VWF assays[c] VWF:Ag (activity), % 111 50–200 VWF:Ag (level), % 105 50–200 VWF:Ag (activity)/VWF:Ag (level) ratio 1.06 Platelet aggregation[d] ADP (6 μM), % 9.1 50.0–100.0 Collagen (5 mg/L), % 17.7 55.0–100.0 Adrenalin (180 μM), % 28.6 55.0–100.0 Arachidonate (0.3 g/L), % 1.0 55.0–100.0 Ristomycin (1.5 g/L), % 52.2 55.0–100.0 Abbreviations: ADP, adenosine diphosphate; aPTT, activated partial thromboplastin time; INR, international normalized ratio; MPV, mean platelet volume; PDW, platelet distribution width; PT, prothrombin time; TT, thrombin time; VWF, von Willebrand factor. a The analysis of blood routine test was accomplished on Mindray CAL8000 hematology system. b The coagulation indicators PT, aPTT, TT, and fibrinogen were determined by coagulation assays using corresponding STA reagents (Diagnostica Stago, France) on a STA MAX automatic coagulation analyzer (Diagnostica Stago, France) according to the manufacturer's instructions. The indicators prothrombin activity and INR were calculated based on the result of PT. c The VWF antigen activity and level were detected by immunoturbidimetric assay using HemosIL VWF activity or antigen kits on ACL TOP 700 automatic coagulation analyzer (Instrumentation Laboratory, United States). d The platelet aggregation tests were conducted by optical turbidimetric assay using Helena platelet aggregation -Abstract Truncated-

Genome-wide linkage analysis and whole-exome sequencing identifies an ITGA2B mutation in a family with thrombocytopenia

[Identification of Two Novel Mutations in ADAMTS13 Gene in a Patient with Hereditary Thrombotic Thrombocytopenic Purpura].

Hereditary thrombocytopenia with platelet sialic acid deficiency and mutations in the GNE genes

Whole exome sequencing for diagnosis of hereditary thrombocytopenia

A mutation of the human EPHB2 gene leads to a major platelet functional defect

Heterozygous ITGA2B Phe1024 Deletion Associated with Abnormal αIIbβ3 Function in a Patient with Congenital Thrombocytopenia

Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura

Comprehensive genetic analysis for identification of monogenic disorders and selection of appropriate treatments in pediatric patients with persistent thrombocytopenia

A Rare Glanzmann Thrombasthenia Pedigree of C.1067T>C Heterozygous Mutation in ITGA2B Gene

Identification Of A Novel Splice Donor Mutation In The Thrombopoietin Gene In A Philippine Family With Hereditary Thrombocythemia

[Developments of high-throughput sequencing-based diagnosis of congenital thrombocytopenia/platelet disorders in a registry study]

Novel Homozygous Silent Mutation of ITGB3 Gene Caused Glanzmann Thrombasthenia

[Genetic Study and Prenatal Diagnosis of a Family with Thrombocytopenia-Absent Radius (TAR) Syndrome].

Whole-genome Sequencing Association Analysis of Quantitative Platelet Traits in A Large Cohort of β-thalassemia

Catheter Intervention in a Patient with Intracranial Aneurysms and Glanzmann Thrombasthenia Caused by a Novel Homozygous Likely Pathogenic Variant in the ITGA2B Gene

Inherited thrombocytopenias: from genes to therapy

Biological, clinical features and modelling of heterozygous variants of glycoprotein Ib platelet subunit alpha (GP1BA) and glycoprotein Ib platelet subunit beta (GP1BB) genes responsible for constitutional thrombocytopenia

Genetic Confirmation and Identification of Novel Variants for Glanzmann Thrombasthenia and Other Inherited Platelet Function Disorders: A Study by the Korean Pediatric Hematology Oncology Group (KPHOG)

SINE-VNTR-Alu Retrotransposon Insertion As a Novel Mutational Event Underlying Glanzmann Thrombasthenia.

Severe Congenital Thrombocytopenia Characterized by Decreased Platelet Sialylation and Moderate Complement Activation Caused by Novel Compound Heterozygous Variants in GNE

A novel frameshift GP1BB mutation causes autosomal dominant macrothrombocytopenia with decreased vWF receptor expression but normal platelet aggregation